Making sense of serotype-specific pneumococcal antibody measurements

Annals of Clinical Biochemistry

Volumn 50, Issue 6, 2013, Pages 517-519

  Beck, Sarah C ^a  

^a PETERBOROUGH CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; EDITORIAL; HIGH RISK POPULATION; HUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; VACCINE FAILURE;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; SPECIES SPECIFICITY; STREPTOCOCCUS PNEUMONIAE;

EID: 84898058378     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213500241     Document Type: Editorial

References (15)

1. Orange JS, Ballow MA, Stiehm RE, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the American academy of allergy, asthma & immunology. J Allergy Clin Immunol 2012; 130: 1-24.
2. Schiffman G, Douglas R, Bonner M, et al. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol methods 1980; 33: 133-144.
3. Sorensen RU, Hidalgo H, et al. Post-immunization pneumococcal antibody titres and IgG subclasses. Paediatr Pulmonol 1996; 22: 197-173.
4. Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weight-based antibody units to a human anti-pneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995; 2: 590-597.
5. Concepcion NF and Frasch CE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8: 266-272.
6. Soininen A, Karpala M, Wahlman SL, et al. Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children. Clin Vaccine Immunol 2002; 9: 1032-1038.
7. Westerink MA, Schroeder HW Jr and Nahm MH. Immune responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination. Aging Dis 2012; 3: 51-67.
8. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-195.
9. Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21: 3265-3275.
10. Siber G, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25: 3816-3826.
11. Landesman SH and Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis 1981; 3: S184-S197.
12. Lawrence EM, Edwards KM, Schiffmann G, et al. Pneumococcal vaccine in normal children. Am J Dis Child 1983; 137: 846-850.
13. Sorensen RU, Levia LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumonia vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998; 17: 685-691.
14. Sorensen RU, Leiva LE, Javier FC, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 1998; 102: 215-221.
15. Wasserman R and Sorensen RU. Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. Pediatr Infect Dis J 1999; 18: 157-163.